The most recent trading session ended with Gilead Sciences (GILD) standing at $105.87, reflecting a -1.53% shift from the previouse trading day's closing. This change lagged the S&P 500's daily loss ...

The landscape for so-called PrEP drugs is evolving rapidly: While Gilead expects FDA approval in June of lenacapvir to be injected twice-a-year to halt the AIDS virus, it is making plans for the ...

Gilead's HIV portfolio remains dominant but faces Medicare Part D pricing pressure, limiting future growth potential. New launches like Livdelzi provide growth opportunities but are unlikely to ...

Warhammer 40,000: Wrath & Glory lets players build their groups from different archetypes. They are brought together as ...

The Zacks Rank system, spanning from #1 (Strong Buy ... Over the last 30 days, the Zacks Consensus EPS estimate has moved 4.9% higher. Gilead Sciences is currently sporting a Zacks Rank of ...

Last year, Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a single injection every six months.

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments. A key highlight was the robust performance in the HIV and oncology segments ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Medicines Agency (EMA) has validated for parallel accelerated review the company’s ...